4.8 Article

HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice

出版社

NATL ACAD SCIENCES
DOI: 10.1073/pnas.1315295110

关键词

CD4bs; glycan; gp160

资金

  1. Stavros Niarchos Foundation
  2. Starr Foundation
  3. Agence Nationale de Recherche sur le Sida
  4. Sidaction
  5. AREVA Foundation
  6. Vaccine Research Institute
  7. Labex Integrative Biology of Emerging Infectious Diseases program
  8. Seventh Framework Programme HIT Hidden HIV [Health-F3-2012-305762]
  9. Institut Pasteur
  10. Bill and Melinda Gates Foundation
  11. Collaboration for AIDS Vaccine Discovery Grants [38660, 38619s]
  12. German Center for Infection Research [UL1 TR000043, AI 100663-01]
  13. Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery
  14. Comprehensive Antibody Vaccine Immune Monitoring Consortium Grant [1032144]
  15. [AI 100148-01]

向作者/读者索取更多资源

Effective control of HIV-1 infection in humans is achieved using combinations of antiretroviral therapy (ART) drugs. In humanized mice (hu-mice), control of viremia can be achieved using either ART or by immunotherapy using combinations of broadly neutralizing antibodies (bNAbs). Here we show that treatment of HIV-1-infected hu-mice with a combination of three highly potent bNAbs not only resulted in complete viremic control but also led to a reduction in cell-associated HIV-1 DNA. Moreover, lowering the initial viral load by coadministration of ART and immunotherapy enabled prolonged viremic control by a single bNAb after ART was withdrawn. Similarly, a single injection of adeno-associated virus directing expression of one bNAb produced durable viremic control after ART was terminated. We conclude that immunotherapy reduces plasma viral load and cell-associated HIV-1 DNA and that decreasing the initial viral load enables single bNAbs to control viremia in hu-mice.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据